Cargando…
Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer
Colorectal cancer is one of the most common malignant tumors and, hence, has become one of the most important public health issues in the world. Treatment with immune checkpoint inhibitors (ICIs) successfully improves the survival rate of patients with melanoma, non‐small‐cell lung cancer, and other...
Autores principales: | Du, Fenqi, Liu, Yanlong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761449/ https://www.ncbi.nlm.nih.gov/pubmed/34817097 http://dx.doi.org/10.1002/jcla.24141 |
Ejemplares similares
-
Immune checkpoint inhibitor‐related molecular markers predict prognosis in extrahepatic cholangiocarcinoma
por: Jin, Bao, et al.
Publicado: (2023) -
Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer
por: Manz, Salomon M., et al.
Publicado: (2021) -
Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022) -
Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update
por: Jung, Gerhard, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
por: Makaremi, Shima, et al.
Publicado: (2021)